<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271817</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-091</org_study_id>
    <secondary_id>2005_091</secondary_id>
    <nct_id>NCT00271817</nct_id>
  </id_info>
  <brief_title>To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)</brief_title>
  <official_title>Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high
      cholesterol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)</measure>
    <time_frame>Baseline and 24 Weeks</time_frame>
    <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides (TG)</measure>
    <time_frame>baseline and 24 Weeks</time_frame>
    <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)</measure>
    <time_frame>Baseline and 64 weeks</time_frame>
    <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides (TG)</measure>
    <time_frame>Baseline and 64 weeks</time_frame>
    <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</measure>
    <time_frame>Baseline and 64 weeks</time_frame>
    <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)</measure>
    <time_frame>Baseline and 64 weeks</time_frame>
    <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1220</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Part 1 - Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ezetimibe/simvastatin combination tablet + niacin (ER)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 -Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ezetimibe/simvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Niacin (ER)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ezetimibe/simvastatin combination tablet + niacin (ER)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ezetimibe/simvastatin combination tablet + niacin (Pbo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: ezetimibe/simvastatin + niacin (ER)</intervention_name>
    <description>ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be ~24 weeks</description>
    <arm_group_label>Part 1 - Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo to ezetimibe/simvastatin</intervention_name>
    <description>ezetimibe/simvastatin (Pbo) tablet. Treatment time will be ~24 weeks.</description>
    <arm_group_label>Part 1 - Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: niacin (ER) tablet</intervention_name>
    <description>niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be ~24 weeks</description>
    <arm_group_label>Part 1 - Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: ezetimibe (+) simvastatin</intervention_name>
    <description>ezetimibe/simvastatin 10/20mg tablet. Treatment time will be ~24 weeks.</description>
    <arm_group_label>Part 1 -Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo to Niacin (ER)</intervention_name>
    <description>Niacin (ER) (Pbo) tablet. Treatment time will be ~24 weeks.</description>
    <arm_group_label>Part 1 -Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: ezetimibe/simvastatin and niacin (ER)</intervention_name>
    <description>ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be ~40 additional weeks for a total of 64 weeks</description>
    <arm_group_label>Part 2 - Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: ezetimibe and simvastatin</intervention_name>
    <description>ezetimibe/simvastatin 10/20mg tablet. Treatment time will be ~40 additional weeks for a total of 64 weeks</description>
    <arm_group_label>Part 2 - Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo to niacin (ER)</intervention_name>
    <description>Niacin (ER) (Pbo) tablet. Treatment time will be ~40 additional weeks for a total of 64 weeks</description>
    <arm_group_label>Part 2 - Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to
             500 mg/dL

          -  Patient willing to be on a low-cholesterol diet

        Exclusion Criteria:

          -  Pregnant or lactating women or intending to become pregnant

          -  Patient with sensitivity or intolerance to ezetimibe, simvastatin, or
             ezetimibe/simvastatin combination tablet

          -  Patient with sensitivity or intolerance ro niacin, any component or niacin extended
             release or aspirin

          -  Patient for whom discontinuation of existing lipid-lowering therapy treatment poses an
             unacceptable risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72. doi: 10.1016/j.jacc.2008.03.003.</citation>
    <PMID>18420099</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2006</study_first_submitted>
  <study_first_submitted_qc>January 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2006</study_first_posted>
  <results_first_submitted>February 13, 2009</results_first_submitted>
  <results_first_submitted_qc>June 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2009</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Niacin</title>
          <description>(Part 1): Niacin titrated to 2000 mg taken orally once daily for 24 weeks. During the first 12 weeks of the study, patients randomized to the niacin containing arms started taking niacin 500 mg and had their niacin dose increased 500 mg every 4 weeks to 2000 mg. Patients in this treatment group were ramdomly reassigned for Part 2 of the study to one of two treatment groups- two-thirds of the patients enrolled in the niacin treatment group were randomly assigned to receive ezetimibe/simvastatin + niacin (ER) and the other one-third were randomly assigned to receive ezetimibe/simvastatin alone.</description>
        </group>
        <group group_id="P2">
          <title>Ezetimibe/Simvastatin</title>
          <description>(Part 1): Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks.
(Part 2): Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Ezetimibe/Simvastatin + Niacin</title>
          <description>(Part 1): Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg as noted above) taken orally once daily for 24 weeks.
(Part 2): Ezetimibe/Simvastatin 10/20 mg + Niacin 2000 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="272"/>
                <participants group_id="P3" count="676"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166">6 patients who completed Part 1 did not continue to Part 2; 1 patient never received drug in Part 2</participants>
                <participants group_id="P2" count="213">1 patient who completed Part 1 did not continue to Part 2</participants>
                <participants group_id="P3" count="391">11 patients who completed Part 1 did not continue to Part 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="285"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="156"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>LDL &lt; 50 mg/dL</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Patients completing the niacin group in Part 1, were re-allocated to one of the two arms in Part 2</participants>
                <participants group_id="P2" count="266">Includes 54 patients re-allocated from the niacin group in Part 1</participants>
                <participants group_id="P3" count="485">Includes 105 patients re-allocated from the niacin group in Part 1</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="234"/>
                <participants group_id="P3" count="401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>LDL &lt; 50 mg/dL</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Niacin</title>
          <description>(Part 1): Niacin titrated to 2000 mg taken orally once daily for 24 weeks. During the first 12 weeks of the study, patients randomized to the niacin containing arms started taking niacin 500 mg and had their niacin dose increased 500 mg every 4 weeks to 2000 mg.</description>
        </group>
        <group group_id="B2">
          <title>Ezetimibe/Simvastatin</title>
          <description>(Part 1): Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks.
(Part 2): Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Ezetimibe/Simvastatin + Niacin</title>
          <description>(Part 1): Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg as noted above) taken orally once daily for 24 weeks.
(Part 2): Ezetimibe/Simvastatin 10/20 mg + Niacin 2000 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="272"/>
            <count group_id="B2" value="272"/>
            <count group_id="B3" value="676"/>
            <count group_id="B4" value="1220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="10.6"/>
                    <measurement group_id="B2" value="57.5" spread="10.3"/>
                    <measurement group_id="B3" value="56.9" spread="10.9"/>
                    <measurement group_id="B4" value="56.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="352"/>
                    <measurement group_id="B4" value="608"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="324"/>
                    <measurement group_id="B4" value="612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="576"/>
                    <measurement group_id="B4" value="1047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;25 kg/m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 to &lt;30 kg/m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="252"/>
                    <measurement group_id="B4" value="481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to &lt;40 kg/m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="251"/>
                    <measurement group_id="B4" value="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 40 kg/m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No BMI Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)</title>
        <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline</description>
        <time_frame>Baseline and 24 Weeks</time_frame>
        <population>The participant population for this analysis is the Completers Population. This includes all patients with a baseline value, who receive at least 24 weeks of active study therapy, and who have an on-treatment measurement at the maximum titrated dose per the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin titrated to 2000 mg taken orally once daily for 24 weeks. During the first 12 weeks of the study, patients randomized to the niacin containing arms had their niacin titrated (increased 500 mg every 4 weeks to 2000 mg).</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin + Niacin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg) taken orally once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)</title>
          <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline</description>
          <population>The participant population for this analysis is the Completers Population. This includes all patients with a baseline value, who receive at least 24 weeks of active study therapy, and who have an on-treatment measurement at the maximum titrated dose per the protocol.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.1" spread="1.3"/>
                    <measurement group_id="O2" value="-58.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, baseline LDL-C, baseline TG, and gender.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-38.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-41.4</ci_lower_limit>
            <ci_upper_limit>-35.4</ci_upper_limit>
            <estimate_desc>Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
        <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>The participant population for this analysis is the Completers Population. This includes all patients with a baseline value, who receive at least 24 weeks of active study therapy, and who have an on-treatment measurement at the maximum titrated dose per the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin titrated to 2000 mg taken orally once daily for 24 weeks. During the first 12 weeks of the study, patients randomized to the niacin containing arms had their niacin titrated (increased 500 mg every 4 weeks to 2000 mg).</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin + Niacin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg) taken orally once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
          <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline</description>
          <population>The participant population for this analysis is the Completers Population. This includes all patients with a baseline value, who receive at least 24 weeks of active study therapy, and who have an on-treatment measurement at the maximum titrated dose per the protocol.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.0" spread="1.3"/>
                    <measurement group_id="O2" value="-55.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, baseline LDL-C, baseline TG, and gender.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-36.5</ci_lower_limit>
            <ci_upper_limit>-30.6</ci_upper_limit>
            <estimate_desc>Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)</title>
        <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>The participant population for this analysis is the Completers Population. This includes all patients with a baseline value, who receive at least 24 weeks of active study therapy, and who have an on-treatment measurement at the maximum titrated dose per the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin + Niacin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg) taken orally once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)</title>
          <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline</description>
          <population>The participant population for this analysis is the Completers Population. This includes all patients with a baseline value, who receive at least 24 weeks of active study therapy, and who have an on-treatment measurement at the maximum titrated dose per the protocol.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="1.3"/>
                    <measurement group_id="O2" value="30.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, baseline LDL-C, baseline TG, and gender.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>18.8</ci_lower_limit>
            <ci_upper_limit>25.3</ci_upper_limit>
            <estimate_desc>Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides (TG)</title>
        <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline</description>
        <time_frame>baseline and 24 Weeks</time_frame>
        <population>The participant population for this analysis is the Completers Population. This includes all patients with a baseline value, who receive at least 24 weeks of active study therapy, and who have an on-treatment measurement at the maximum titrated dose per the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin + Niacin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg) taken orally once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides (TG)</title>
          <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline</description>
          <population>The participant population for this analysis is the Completers Population. This includes all patients with a baseline value, who receive at least 24 weeks of active study therapy, and who have an on-treatment measurement at the maximum titrated dose per the protocol.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" spread="29.7"/>
                    <measurement group_id="O2" value="-42.5" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA using ranks based on normal scores (Tukey method) with model terms for treatment, baseline LDL-C, baseline TG and gender</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-18.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-22.6</ci_lower_limit>
            <ci_upper_limit>-14.7</ci_upper_limit>
            <estimate_desc>Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin
The median difference is based on the Hodges-Lehmann estimates of shift; The distribution-free 95% CI is based on Wilcoxonâ€™s rank sum test statistic.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)</title>
        <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline</description>
        <time_frame>Baseline and 64 weeks</time_frame>
        <population>The analysis population is the modified intention-to-treat population, which includes patients that were randomized to ezetimibe/simvastatin + niacin or ezetimibe/simvastatin treatment groups and have a baseline measurement and at least on measurement beyond Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks. Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin + Niacin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg) taken orally once daily for 24 weeks. Ezetimibe/Simvastatin 10/20 mg + Niacin 2000 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)</title>
          <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline</description>
          <population>The analysis population is the modified intention-to-treat population, which includes patients that were randomized to ezetimibe/simvastatin + niacin or ezetimibe/simvastatin treatment groups and have a baseline measurement and at least on measurement beyond Week 24.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="1.4"/>
                    <measurement group_id="O2" value="30.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, baseline LDL-C, baseline TG, and gender.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>18.0</ci_lower_limit>
            <ci_upper_limit>25.0</ci_upper_limit>
            <estimate_desc>Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides (TG)</title>
        <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline</description>
        <time_frame>Baseline and 64 weeks</time_frame>
        <population>The analysis population is the modified intention-to-treat population, which includes patients that were randomized to ezetimibe/simvastatin + niacin or ezetimibe/simvastatin treatment groups and have a baseline measurement and at least on measurement beyond Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks. Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin + Niacin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg) taken orally once daily for 24 weeks. Ezetimibe/Simvastatin 10/20 mg + Niacin 2000 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides (TG)</title>
          <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline</description>
          <population>The analysis population is the modified intention-to-treat population, which includes patients that were randomized to ezetimibe/simvastatin + niacin or ezetimibe/simvastatin treatment groups and have a baseline measurement and at least on measurement beyond Week 24.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" spread="32.7"/>
                    <measurement group_id="O2" value="-44.5" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA using ranks based on normal scores (Tukey method) with model terms for treatment, baseline LDL-C, baseline TG and gender.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-17.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-21.8</ci_lower_limit>
            <ci_upper_limit>-13.6</ci_upper_limit>
            <estimate_desc>Median difference = Ezetimibe/Simvastatin + Niacin minus Ezetimibe/Simvastatin
The median difference is based on the Hodges-Lehmann estimates of shift; The distribution-free 95% CI is based on Wilcoxonâ€™s rank sum test statistic.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
        <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline</description>
        <time_frame>Baseline and 64 weeks</time_frame>
        <population>The analysis population is the modified intention-to-treat population, which includes patients that were randomized to ezetimibe/simvastatin + niacin or ezetimibe/simvastatin treatment groups and have a baseline measurement and at least on measurement beyond Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks. Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin + Niacin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg) taken orally once daily for 24 weeks. Ezetimibe/Simvastatin 10/20 mg + Niacin 2000 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
          <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline</description>
          <population>The analysis population is the modified intention-to-treat population, which includes patients that were randomized to ezetimibe/simvastatin + niacin or ezetimibe/simvastatin treatment groups and have a baseline measurement and at least on measurement beyond Week 24.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.1" spread="1.3"/>
                    <measurement group_id="O2" value="-52.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, baseline LDL-C, baseline TG, and gender.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.4</ci_lower_limit>
            <ci_upper_limit>-4.2</ci_upper_limit>
            <estimate_desc>Median difference = Ezetimibe/Simvastatin + Niacin minus Ezetimibe/Simvastatin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)</title>
        <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline</description>
        <time_frame>Baseline and 64 weeks</time_frame>
        <population>The analysis population is the modified intention-to-treat population, which includes patients that were randomized to ezetimibe/simvastatin + niacin or ezetimibe/simvastatin treatment groups and have a baseline measurement and at least on measurement beyond Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks. Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin + Niacin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg) taken orally once daily for 24 weeks. Ezetimibe/Simvastatin 10/20 mg + Niacin 2000 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)</title>
          <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline</description>
          <population>The analysis population is the modified intention-to-treat population, which includes patients that were randomized to ezetimibe/simvastatin + niacin or ezetimibe/simvastatin treatment groups and have a baseline measurement and at least on measurement beyond Week 24.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.3" spread="1.3"/>
                    <measurement group_id="O2" value="-54.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, baseline LDL-C, baseline TG, and gender.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
            <estimate_desc>Mean difference = Ezetimibe/Simvastatin + Niacin minus Ezetimibe/Simvastatin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)</title>
        <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>The participant population for this analysis is the Completers Population. This includes all patients with a baseline value, who receive at least 24 weeks of active study therapy, and who have an on-treatment measurement at the maximum titrated dose per the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin + Niacin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg) taken orally once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)</title>
          <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline</description>
          <population>The participant population for this analysis is the Completers Population. This includes all patients with a baseline value, who receive at least 24 weeks of active study therapy, and who have an on-treatment measurement at the maximum titrated dose per the protocol.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.5" spread="1.2"/>
                    <measurement group_id="O2" value="-58.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, baseline LDL-C, baseline TG, and gender.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>-2.1</ci_upper_limit>
            <estimate_desc>Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
        <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>The analysis population is the modified intention-to-treat population, which includes patients that were randomized to ezetimibe/simvastatin + niacin or ezetimibe/simvastatin treatment groups and have a baseline measurement and at least on measurement beyond Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin + Niacin</title>
            <description>Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg) taken orally once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
          <description>Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline</description>
          <population>The analysis population is the modified intention-to-treat population, which includes patients that were randomized to ezetimibe/simvastatin + niacin or ezetimibe/simvastatin treatment groups and have a baseline measurement and at least on measurement beyond Week 24.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.9" spread="1.1"/>
                    <measurement group_id="O2" value="-55.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, baseline LDL-C, baseline TG, and gender.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.4</ci_lower_limit>
            <ci_upper_limit>-5.0</ci_upper_limit>
            <estimate_desc>Mean difference = Ezetimibe/Simvastatin + Niacin minus Ezetimibe/Simvastatin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Niacin</title>
          <description>Niacin group from Part 1</description>
        </group>
        <group group_id="E2">
          <title>Ezetimibe/Simvastatin</title>
          <description>Ezetimibe/Simvastatin group from Part 1</description>
        </group>
        <group group_id="E3">
          <title>Ezetimibe/Simvastatin + Niacin</title>
          <description>Ezetimibe/Simvastatin + Niacin group from Part 1</description>
        </group>
        <group group_id="E4">
          <title>Ezetimibe/Simvastatin - Part 2</title>
          <description>EZ/Simva group from Part 2 All-Treated Patient as Treated Population</description>
        </group>
        <group group_id="E5">
          <title>Ezetimibe/Simvastatin + Niacin - Part 2</title>
          <description>Ezetimibe/Simvastatin + Niacin group from Part 2 All-Treated Patient as Treated Population</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8"/>
                <counts group_id="E2" subjects_affected="13"/>
                <counts group_id="E3" subjects_affected="16"/>
                <counts group_id="E4" subjects_affected="29"/>
                <counts group_id="E5" subjects_affected="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Aplastic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pancreatic Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Perirectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Rocky Mountain Spotted Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Viral Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Ligament Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Breast Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Lip Neoplasm Malignant Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Metastases To Liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Metastases To Lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cervical Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121"/>
                <counts group_id="E2" subjects_affected="428"/>
                <counts group_id="E3" subjects_affected="185"/>
                <counts group_id="E4" subjects_affected="175"/>
                <counts group_id="E5" subjects_affected="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="86" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="274" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="288" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="326"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Part 1 population is all patients enrolled in Part 1 of the study. Part 2 is those patients who received either niacin, ezetimibe/simvastatin, or ezetimibe/simvastatin + niacin during Part 1 until they finished the study at week 64 or discontinued.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

